Vir Biotechnology, Inc. (VIR)
- Previous Close
8.10 - Open
8.10 - Bid 8.11 x 400
- Ask 8.15 x 300
- Day's Range
8.08 - 8.29 - 52 Week Range
7.72 - 27.48 - Volume
762,454 - Avg. Volume
1,077,337 - Market Cap (intraday)
1.103B - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
-- - EPS (TTM)
-4.59 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.29
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.
www.vir.bioRecent News: VIR
Performance Overview: VIR
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VIR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VIR
Valuation Measures
Market Cap
1.10B
Enterprise Value
-297.53M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
27.51
Price/Book (mrq)
0.69
Enterprise Value/Revenue
-7.53
Enterprise Value/EBITDA
0.45
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.48%
Return on Equity (ttm)
-33.54%
Revenue (ttm)
86.18M
Net Income Avi to Common (ttm)
-615.06M
Diluted EPS (ttm)
-4.59
Balance Sheet and Cash Flow
Total Cash (mrq)
1.52B
Total Debt/Equity (mrq)
7.83%
Levered Free Cash Flow (ttm)
-596.45M
Research Analysis: VIR
Company Insights: VIR
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: VIR
VIR: Lowering target price to $9.00
VIR BIOTECHNOLOGY INC has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetVIR: Raising target price to $10.00
VIR BIOTECHNOLOGY INC has an Investment Rating of HOLD; a target price of $10.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetVIR: Rating increased to a HOLD
VIR BIOTECHNOLOGY INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetVIR: What does Argus have to say about VIR?
VIR BIOTECHNOLOGY INC has an Investment Rating of SELL; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target